| Literature DB >> 25426853 |
Makaoui Maatallah1, Malin Vading2, Muhammad Humaun Kabir3, Amina Bakhrouf1, Mats Kalin4, Pontus Nauclér4, Sylvain Brisse5, Christian G Giske3.
Abstract
Clinical isolates of Klebsiella pneumoniae are divided into three phylogroups and differ in their virulence factor contents. The aim of this study was to determine an association between phylogroup, virulence factors and mortality following bloodstream infection (BSI) caused by Klebsiella pneumoniae. Isolates from all adult patients with BSI caused by K. pneumoniae admitted to Karolinska University Hospital, Solna between 2007 and 2009 (n = 139) were included in the study. Phylogenetic analysis was performed based on multilocus sequence typing (MLST) data. Testing for mucoid phenotype, multiplex PCR determining serotypes K1, K2, K5, K20, K54 and K57, and testing for virulence factors connected to more severe disease in previous studies, was also performed. Data was retrieved from medical records including age, sex, comorbidity, central and urinary catheters, time to adequate treatment, hospital-acquired infection, and mortality, to identify risk factors. The primary end-point was 30- day mortality. The three K. pneumoniae phylogroups were represented: KpI (n = 96), KpII (corresponding to K. quasipneumoniae, n = 9) and KpIII (corresponding to K. variicola, n = 34). Phylogroups were not significantly different in baseline characteristics. Overall, the 30-day mortality was 24/139 (17.3%). Isolates belonging to KpIII were associated with the highest 30-day mortality (10/34 cases, 29.4%), whereas KpI isolates were associated with mortality in 13/96 cases (13.5%). This difference was significant both in univariate statistical analysis (P = 0.037) and in multivariate analysis adjusting for age and comorbidity (OR 3.03 (95% CI: 1.10-8.36). Only three of the isolates causing mortality within 30 days belonged to any of the virulent serotypes (K54, n = 1), had a mucoid phenotype (n = 1) and/or contained virulence genes (wcaG n = 1 and wcaG/allS n = 1). In conclusion, the results indicate higher mortality among patients infected with isolates belonging to K. variicola. The increased mortality could not be related to any known virulence factors, including virulent capsular types or mucoid phenotype.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25426853 PMCID: PMC4245126 DOI: 10.1371/journal.pone.0113539
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Phylogenetic representation of all isolates.
A: Radial phylogenetic tree of 139 isolates based on the concatenated sequences of seven MLST loci performed using the Neighbor-joining method based on a Jukes-Cantor distance matrix. Main bootstrap values obtained are highlighted on at the main node of the phylogeny. The tree was rooted using the nucleotide sequences of the seven genes of E. coli and considered as an out-group. Each phylogroup was clearly separated from others. Colors of isolates symbols are specific of each phylogroups. Blue color corresponds to the KpI phylogroup, green corresponds to KpII, and red corresponds to KpIII. Empty symbols correspond to the references strains specific for each phylogroups. B: Minimal Spanning Tree (MST) analysis of Klebsiella pneumoniae strains based on MLST allelic profiles. Each circle corresponds to an ST. The area of each circle corresponds to the number of isolates. The relationships between strains are indicated by the connections between the isolates and the lengths of the branches linking them. Black lines connecting pairs of STs indicate that they differ in one allele (thick lines), two and three alleles (thin), or four to seven alleles (dashed). Colors of isolates symbols are specific to each phylogroup: blue - KpI, green - KpII and red - KpIII. Grey zones surround STs differing in one allele forming a clonal complex. C: NeighborNet graph based on seven concatenated housekeeping genes, illustrating the recombination within and among phylogroups. Colors surrounding each zone are specific of each phylogroup. Blue color corresponds to the KpI phylogroup, green corresponds to KpII, and red corresponds to KpIII.
Nucleotide polymorphism within the seven housekeeping genes used for MLST.
| Alleles | n | Sites | NetSites | S | Hap | Hd | π | θ | Ka/Ks |
|
| 139 | 450 | 450 | 23 | 18 | 0.692 | 0.00819 | 0.009683 | 0.09948677 |
|
| 139 | 318 | 318 | 28 | 19 | 0.756 | 0.015221 | 0.017127 | 0 |
|
| 139 | 477 | 477 | 59 | 26 | 0.805 | 0.027967 | 0.023598 | 0.03242491 |
|
| 139 | 432 | 432 | 54 | 28 | 0.693 | 0.02405 | 0.023955 | 0.01440774 |
|
| 139 | 420 | 420 | 41 | 41 | 0.939 | 0.014013 | 0.020316 | 0.00640582 |
|
| 139 | 501 | 501 | 41 | 27 | 0.815 | 0.014476 | 0.015582 | 0.02302211 |
|
| 139 | 438 | 402 | 79 | 47 | 0.952 | 0.046675 | 0.040646 | 0.06934406 |
|
| 139 | 3036 | 3000 | 325 | 115 | 0.996 | 0.021386 | 0.021363 | 0.03443384 |
|
| 96 | 3024 | 3006 | 115 | 75 | 0.993 | 0.003715 | 0.007448 | 0.07781457 |
|
| 9 | 3018 | 3012 | 105 | 9 | 1 | 0.013206 | 0.012949 | 0.02047211 |
|
| 34 | 3018 | 3006 | 155 | 31 | 0.995 | 0.006379 | 0.012936 | 0.01251564 |
N = number of STs or samples subjected for analysis. Sites = length of sequences after alignments. Net Sites = length of sequences subjected for analysis (the gaps or missing data are rejected from analysis). S = polymorphic sites. Hap = haplotypes. Hd = haplotypic diversity. π = nucleotide diversity. θ = average number of nucleotide differences per site. Ka/Ks = ratio of the number of non-synonymous substitutions per non-synonymous site (Ka) to the number of synonymous substitutions per synonymous site (Ks).
eBURST analysis of the MLST data: illustration of clonal complexes based on STs and their allelic profiles.
| Clonal Complexes | STs | Allelic profiles |
| CC347 | 347 | 16, 24, 21, 27, 47, 22, 67 |
| 596 | 16, 24, 21, 27, 41, 22, 67 | |
| 595 | 16, 24, 21, 27, 55, 22, 67 | |
| 619 | 64, 24, 21, 27, 47, 22, 67 | |
| 197 | 16, 28, 21, 27, 47, 22, 67 | |
| 642 | 16, 24, 21, 24, 47, 22, 67 | |
| 597 | 16, 24, 21, 27, 47, 22, 105 | |
| CC253 | 253 | 2, 1, 1, 1, 9, 1, 13 |
| 704 | 2, 1, 1, 1, 9, 1, 20 | |
| 163 | 2, 1, 1, 1, 9, 1, 12 | |
| 588 | 2, 1, 1, 1, 9, 1, 23 | |
| 618 | 2, 1, 1, 1, 116, 1, 13 | |
| CC25 | 25 | 2, 1, 1, 1, 10, 4, 13 |
| 65 | 2, 1, 2, 1, 10, 4, 13 | |
| 280 | 2, 1, 2, 1, 10, 4, 46 | |
| 304 | 2, 1, 1, 1, 10, 4, 90 | |
| CC268 | 268 | 2, 1, 2, 1, 7, 1, 81 |
| 703 | 16, 1, 2, 1, 7, 1, 7 | |
| 701 | 2, 1, 2, 2, 7, 1, 81 | |
| 36 | 2, 1, 2, 1, 7, 1, 7 | |
| CC17 | 17 | 2, 1, 1, 1, 4, 4, 4 |
| 20 | 2, 3, 1, 1, 4, 4, 4 | |
| 336 | 2, 1, 1, 1, 72, 4, 4 | |
| CCI | 504 | 2, 1, 1, 1, 3, 3, 18 |
| 540 | 2, 1, 71, 1, 3, 3, 18 | |
| CCII | 35 | 2, 1, 2, 1, 10, 1, 19 |
| 693 | 2, 1, 2, 1, 10, 3, 19 | |
| CCIII | 357 | 16, 24, 21, 27, 54, 22, 45 |
| 599 | 16, 24, 21, 27, 111, 22, 45 | |
| CCIV | 541 | 4, 1, 2, 1, 1, 1, 4 |
| 584 | 4, 1, 2, 1, 1, 7, 4 | |
| CCV | 15 | 1, 1, 1, 1, 1, 1, 1 |
| 14 | 1, 6, 1, 1, 1, 1, 1 | |
| CCVI | 13 | 2, 3, 1, 1, 10, 1, 19 |
| 591 | 2, 3, 1, 1, 7, 1, 19 | |
| CCVII | 593 | 2, 1, 2, 1, 9, 1, 16 |
| 429 | 2, 1, 2, 1, 9, 1, 116 |
CCI to CCVII are an arbitrary designations of clonal complexes found in the present study, each complex formed only by two STs.
Comparison between patients with 30-day mortality and survivors.
| Dead within 30 days (n = 23) No. (%) | Survivors>30 days (n = 107) No. (%) | Dead vs. Survivors Significance P<0.05 | |
|
| |||
| Median age, years | 73 | 68 | 0.35 |
| Male sex | 14 (60.9) | 70 (65.4) | 0.68 |
| Charlson index (median) | 5 | 2 |
|
| Charlson index 0–1 | 1 (4.4) | 17 (15.9) |
|
| Charlson index 2–3 | 8 (34.8) | 62 (57.9) | |
| Charlson index 4–5 | 3 (13.0) | 12 (11.2) | |
| Charlson index>5 | 11 (47.8) | 16 (15.0) | |
| Diabetes | 2 (8.7) | 20 (18.7) | 0.25 |
| Heart disease | 8 (34.8) | 28 (26.2) | 0.40 |
| Pulmonary disease | 7 (30.4) | 15 (14.0) | 0.070 |
| Kidney disease | 4 (17.4) | 18 (16.8) | 1.00 |
| Liver disease | 6 (26.1) | 16 (15.0) | 0.22 |
| CNS-disease | 5 (21.7) | 17 (15.9) | 0.54 |
| Intestinal disease | 3 (13.0) | 13 (12.1) | 1.00 |
| Malignancy, all | 15 (62.5) | 60 (56.1) | 0.42 |
| Hematological | 3 (13.0) | 21 (19.6) | 0.57 |
| Urogenital | 5 (21.7) | 18 (16.8) | 0.56 |
| Colorectal | 1 (4.3) | 10 (9.3) | 0.69 |
| Pulmonary | 3 (13.0) | 3 (2.8) | 0.068 |
| Bile/liver/pancreas | 1 (4.3) | 5 (4.7) | 1.00 |
| Miscellaneous | 2 (8.7) | 3 (2.8) | 0.21 |
| Metastasized | 10 (43.5) | 12 (11.2) |
|
| Previous organ transplant | 1 (4.3) | 2 (1.9) | 0.45 |
| Neutropenia | 2 (8.7) | 19 (17.8) | 0.37 |
| Hospital-acquired infection | 11 (47.8) | 54 (50.5) | 0.82 |
| Urinary catheter | 9 (39.1) | 41 (38.3) | 0.94 |
| Central catheter | 7 (30.4) | 33 (30.8) | 0.97 |
| Polymicrobial | 8 (34.8) | 24 (22.4) | 0.21 |
|
| 5 (21.7) | 9 (8.4) | 0.074 |
| Source of infection | |||
| Urinary | 7 (30.4) | 47 | 0.23 |
| Respiratory tract | 3 (13.0) | 5 (4.7) | 0.15 |
| Bile/liver | 1 (4.3) | 10 | 0.69 |
| Gastrointestinal tract | 3 (13.0) | 6 (5.6) | 0.20 |
| Miscellaneous | 3 (13.0) | 10 | 0.59 |
| Unknown | 6 (26.1) | 29 (27.1) | 0.92 |
| Time to adequate antimicrobial therapy | |||
| 0–1 h | 2 (8.7) | 12 (11.2) | 0.98 |
| 1–2 h | 6 (26.1) | 21 (19.6) | |
| 2–4 h | 6 (26.1) | 28 (26.2) | |
| 4–24 h | 6 (26.1) | 33 (30.8) | |
| 24–48 | 2 (8.7) | 9 (8.4) | |
| >48 h | 1 (4.4) | 4 (3.7) | |
|
| |||
| KpIII | 10 (43.5) | 24 (22.4) |
|
| Mucoid phenotype | 1 (4.3) | 7 (6.5) | 1.00 |
| Serotypability | 1 (4.3) | 17 (15.9) | 0.20 |
| Virulence genes | 1 (4.3) | 17 (15.9) | 0.20 |
| Any virulence factor | 2 (8.7) | 29 (27.1) | 0.060 |
| ESBL | 1 (4.3) | 4 (3.7) | 1.00 |
*Compared to KpI where the prevalence was 56.5% (13/23) in patients who died and. 77.6% (83/107) in patients who survived.
Clinical characteristics of patients with invasive infection caused by K. pneumoniae/variicola .
| All (n = 139) No. (%) | KpI (n = 96) No. (%) | KpIII (n = 34) No. (%) | KpI vs. KpIII Significance P<0.05 | |
| Age, median, years | 70 | 65.1 | 68 | 0.62 |
| Male sex | 87 (62.6) | 58 (60.4) | 26 (76.5) | 0.093 |
| Charlson index, median | 2 (0–9) | 2 (0–9) | 3 (1–7) | 0.37 |
| Charlson index 0–1 | 18 (12.9) | 17 (17.7) | 1 (2.9) | 0.07 |
| Charlson index 2–3 | 76 (54.7) | 47 (49.0) | 23 (67.7) | |
| Charlson index 4–5 | 15 (10.8) | 10 (10.4) | 5 (14.7) | |
| Charlson index>5 | 30 (21.6) | 22 (22.9) | 5 (14.7) | |
| Diabetes | 24 (17.3) | 15 (15.6) | 7 (20.6) | 0.51 |
| Heart disease | 38 (27.3) | 25 (26.0) | 11 (32.4) | 0.48 |
| Pulmonary disease | 25 (18.0) | 14 (14.6) | 8 (23.5) | 0.23 |
| Kidney disease | 25 (18.0) | 17 (17.7) | 5 (14.7) | 0.69 |
| Liver disease | 22 (15.8) | 16 (16.7) | 6 (17.6) | 0.90 |
| CNS-disease | 24 (17.3) | 18 (18.8) | 5 (14.7) | 0.60 |
| Intestinal disease | 17 (12.2) | 13 (13.5) | 6 (17.6) | 0.56 |
| Malignancy, all | 81 (58.3) | 51 (53.1) | 21 61.8) | 0.38 |
| Hematologic | 26 (18.7) | 16 (16.7) | 8 (23.5) | 0.38 |
| Urogenital | 25 (18.0) | 18 (18.8) | 5 (14.7) | 0.60 |
| Colorectal | 11 (7.9) | 7 (7.3) | 4 (11.8) | 0.48 |
| Pulmonary | 7 (5.0) | 4 (4.2) | 3 (8.8) | 0.38 |
| Bile/liver/pancreas | 6 (4.3) | 6 (6.3) | 0 | 0.34 |
| Miscellaneous | 6 (4.3) | 3 (3.1) | 2 (5.9) | 0.61 |
| Metastasized | 26 (18.7) | 18 (18.8) | 5 (14.7) | 0.60 |
| Prev. organ transplant | 4 (2.9) | 3 (3.1) | 0 (0) | 0.57 |
| Neutropenia | 24 (17.3) | 14 (14.6) | 7 (20.6) | 0.42 |
| Hospital-acquired infection | 68 (48.9) | 50 (52.1) | 14 (41.2) | 0.27 |
| Urinary catheter | 54 (38.8) | 40 (41.7) | 10 (29.4) | 0.21 |
| Central catheter | 43 (30.9) | 28 (29.2) | 12 (35.3) | 0.51 |
| Source of infection | ||||
| Urinary | 59 (42.4) | 42 (43.8) | 12 (35.3) | 0.39 |
| Respiratory tract | 8 (5.8) | 6 (6.3) | 2 (5.9) | 1.00 |
| Bile/liver | 11 (7.9) | 9 (9.4) | 2 (5.9) | 0.73 |
| Gastrointestinal tract | 9 (6.5) | 4 (4.2) | 5 (14.7) | 0.052 |
| Miscellaneous | 14 (10.1) | 11 (11.5) | 2 (5.9) | 0.51 |
| Unknown | 38 (27.3) | 26 (27.1) | 11 (32.4) | 0.63 |
| Polymicrobial (all) | 34 (24.5) | 21 (21.9) | 11 (32.4) | 0.22 |
|
| 15 (10.8) | 9 (9.4) | 5 (14.7) | 0.52 |
|
| 5 (3.6) | 3 (3.1) | 1 (2.9) | 1.00 |
|
| 5 (3.6) | 2 (2.1) | 2 (5.9) | 0.28 |
No of isolates with non-susceptibility (intermediate and resistant) to antimicrobials.
| Antimicrobial | All (139) | KpI (n = 96) | KpIII (n = 34) | KpI vs. KpIII Significance P<0.05 |
| Ciprofloxacin | 12 (8.6) | 10 (10.4) | 2 (5.9) | 0.73 |
| Trimethoprim/sulfametoxazole | 15 (10.8) | 15 (15.6) | 0 |
|
| Cefotaxime | 5 (3.6) | 5 (5.2) | 0 | 0.33 |
| Ceftazidime | 6 (4.3) | 5 (5.2) | 0 | 0.33 |
| Gentamicin | 5 (3.6) | 5 (5.2) | 0 | 0.33 |
| Piperacillin/tazobactam | 8 (5.8) | 8 (8.3) | 0 | 0.11 |
| Meropenem | 1 (0.7) | 1 (1.0) | 0 | 1.00 |
| Multidrug-resistance (I or R ≥3 classes of antibiotics) | 5 (3.6) | 5 (5.2) | 0 | 0.33 |
| ESBL | 5 (3.6) | 5 (5.2) | 0 | 0.33 |
| CPE (ESBLCARBA) | 1 (0.7) | 1 (1.0) | 0 | 1.00 |
| Total isolates with resistance to any group above | 21 (15.1) | 18 (18.8) | 2 (5.9) | 0.074 |
CPE = carbapenemase-producing Enterobacteriaceae.
*Two isolates CTX-M-1, one SHV-ESBL, one CTX-M-1+SHV-ESBL in genotypic analysis.
**VIM, CTX-M-1, CMY-2 in genotypic analysis.